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Update: Adverse Event Data and Revised
American Thoracic Society/CDC
Recommendations Against the Use of Rifampin
and Pyrazinamide for Treatment of Latent
Tuberculosis Infection---United States, 2003
CDC has reported previously surveillance data of severe liver injury in patients treated for latent
tuberculosis infection (LTBI) with a daily and twice-weekly 2-month* regimen of rifampin with
pyrazinamide (RZ). On the basis of these initial reports, CDC cautioned clinicians in the use of this therapy
with advised additional monitoring (1--4). To estimate the incidence of RZ-associated severe liver injury
and provide more precise data to guide treatment for LTBI, CDC collected data from cohorts of patients in
the United States who received RZ for the treatment of LTBI during January 2000--June 2002 and for
whom data were reported to CDC through June 6, 2003. This report summarizes the analysis, which found
high rates of hospitalization and death from liver injury associated with the use of RZ. On the basis of these
findings, the American Thoracic Society (ATS) and CDC now recommend that this regimen should
generally not be offered to persons with LTBI. The revised ATS/CDC recommendations described in this
report have been endorsed by the Infectious Diseases Society of America (IDSA). Clinicians are advised to
use the recommended alternative regimens for the treatment of LTBI (Table). Rifampin and pyrazinamide
(PZA) should continue to be administered in multidrug regimens for the treatment of persons with active
tuberculosis (TB) disease (5).
For surveillance purposes, a case of severe liver injury was defined as one leading to the hospitalization or
death of a patient being treated for LTBI with RZ (2). During October 2000--June 2003, CDC received
reports of 48 patients who had confirmed cases; 33 (69%) cases occurred in the second month of treatment.
A total of 11 (23%) patients died†, including two persons known to be infected with human
immunodeficiency virus (HIV).
A two-phase retrospective survey was conducted to estimate the incidence of severe liver injury among
persons receiving RZ for treatment of LTBI. In December 2001 (phase I), CDC sent a questionnaire by e-
mail to TB-control programs in 12 large cities and all 50 states, asking them to identify programs and
health-care providers prescribing RZ for treatment of LTBI. All controllers responded, and in February
2002, CDC staff called the programs and health-care providers identified as prescribing RZ for LTBI to
confirm its use. In September 2002 (phase II), CDC mailed a second questionnaire to the 150 health-care
providers identified during the first phase, requesting aggregate cohort data for January 2000--June 2002;
109 (78%) health-care providers responded by June 6, 2003.
Of 7,737 patients who were reported to have started RZ for treatment of LTBI during the survey period,
5,980 (77%) received daily doses, and 1,757 (23%) received twice-weekly doses. A total of 204 patients
discontinued using RZ because of aspartate aminotransferase (AST) concentrations greater than five times
the upper limit of normal (rate: 26.4 per 1,000 treatment initiations; 95% confidence interval (CI) = 22.8-
-30.0). An additional 146 patients discontinued using RZ because of symptoms of hepatitis (rate: 18.9 per
1,000 treatment initiations; 95% CI = 17.4--20.4).
Of the 48 cases of severe liver injury reported to CDC through passive surveillance, 30 also were detected
in the second phase of the survey. Of the 18 patients whose cases were not detected, six patients had liver
injuries outside the survey period, five patients' health-care providers did not respond to the questionnaire,
and seven (six of whom were in private practice) were not identified in the first phase of the survey. Of the
30 patients whose cases were detected, 23 (77%) recovered, and seven (23%) died. On the basis of these 30
cases, the estimated rates of hospitalization and death during the survey period were 3.0 (95% CI = 1.8--4.2)
and 0.9 (95% CI = 0.2--1.6) per 1,000 treatment initiations, respectively.
Reported by: State and territorial health depts. Div of Tuberculosis Elimination, National Center for HIV,
STD, and TB Prevention, CDC.
Editorial Note:
The CDC cohort analysis found that the rates of severe liver injury and death related to the use of RZ are
higher than the rates for isoniazid (INH)-associated liver injury in the treatment of LTBI. Although initial
studies attributed hospitalization rates as high as 5.0 per 1,000 treatment initiations and mortality rates as
high as 1.0 per 1,000 to INH (6,7), studies conducted since 1991 involving more than one million persons
treated with INH have reported hospitalization rates of 0.1--0.2 (median: 0.15) and mortality rates of 0--0.3
per 1,000 (median: 0.04) (4,8,9). This decrease from earlier studies might reflect careful selection of
patients and active monitoring for early signs of adverse events. In addition to the survey on the use of RZ
described in this report, recent studies have reported episodes of liver injury and hospitalization associated
with RZ for treatment of LTBI (10,11), including the need for transplantation in one patient (12). Among
first-line agents in the treatment of active TB disease, pyrazinamide (PZA) might be the most hepatotoxic
(13).
These data and other recent studies (4,10,11,14--16) were reviewed by TB experts§ at a meeting held during
the 99th International ATS Conference in Seattle, Washington, on May 12, 2003, to discuss proposed
revisions to guidelines for the treatment of LTBI. ATS and CDC now recommend that this regimen should
generally not be offered to persons with LTBI for either HIV-negative or HIV-infected persons. On the basis
of the investigation of potential cofactors in the 48 patients with serious liver injury, this regimen should
never be offered to patients who 1) are concurrently taking other medications associated with liver injury; 2)
drink excessive amounts of alcohol, even if alcohol use is discontinued during treatment; 3) have
underlying liver disease; or 4) have a history of INH-associated liver injury.
If the potential benefits of this regimen outweigh the risk for severe liver injury and death associated with it,
use of RZ might be considered in carefully selected patients, but only if 1) the preferred or alternative
regimens (i.e., 9 months of daily or biweekly INH, 6 months of daily or biweekly INH, or 4 months of daily
rifampin) are judged not likely to be completed and 2) oversight by a clinician with expertise in the
treatment of LTBI can be provided. A TB/LTBI expert should be consulted before RZ is offered. In
addition, patients should be asked whether they have had liver disease or adverse effects from taking INH or
other drugs, informed of potential hepatotoxicity of the RZ regimen, and advised against the concurrent use
of potentially hepatotoxic drugs, including over-the-counter drugs such as acetaminophen.
To facilitate periodic clinical assessments of persons taking an RZ regimen (2), clinicians should dispense
no more than a 2-week supply (with a daily PZA dose of <20.0 mg/kg/d [maximum daily PZA dose: 2.0 g],
and a twice-weekly dose of <50.0 mg/kg/d [maximum twice-weekly PZA dose: 4.0 g]). Patients should be
reassessed in person by a health-care provider at 2, 4, 6, and 8 weeks of treatment for adherence, tolerance,
and adverse effects. The 8-week assessment also should be used to document treatment completion. At each
visit, health-care providers who speak the patient's own language should instruct the patient to stop taking
RZ immediately and seek medical consultation if abdominal pain, emesis, jaundice, or other symptoms of
hepatitis develop. Provider continuity is recommended for optimal monitoring.
For persons taking this regimen, serum aminotransaminases (AT) and bilirubin should be measured at
baseline and at 2, 4, 6, and 8¶ weeks of treatment. Because the majority of these patients had onset of
symptoms of liver injury after the fourth week of therapy (Figure), patients should be monitored throughout
the entire course of treatment. Use of RZ should be discontinued immediately and not resumed for any of
the following findings: 1) AT greater than five times the upper limit of normal range in an asymptomatic
person, 2) AT greater than normal range when accompanied by symptoms of hepatitis, or 3) a serum
bilirubin concentration greater than the normal range, whether or not symptoms are present.
The risk for progression from LTBI to active TB is increased substantially in persons with HIV infection
(4). Therefore, as recommended previously for the treatment of all persons in whom LTBI is diagnosed,
voluntary HIV counseling and testing should be offered routinely.
For progression to TB disease to be prevented, persons with LTBI should be identified in contact
investigations and targeted screening programs and should complete treatment with safe and effective
regimens. The successful treatment of LTBI is an essential component of the TB elimination strategy in the
United States (4). In addition to this report, CDC and its partners are sending a letter to TB-control
programs in 12 large cities and all 50 states and organizations active in TB control (e.g., the National
Coalition to Eliminate Tuberculosis). To reach clinicians who are treating patients with LTBI, primary care
medical associations (e.g., the American Medical Association and the American College of Physicians) are
distributing this report to their members. This report and the letter are available at http://www.cdc.gov/tb.
The letter is being added to the April 2000 CDC Targeted Tuberculin Testing and Treatment of Latent TB
Infection Guidelines, and existing provider educational materials are being revised.
The recommendations against the use of RZ for treatment of LTBI described in this report do not apply to
the appropriate use of rifampin and PZA in multidrug regimens for the treatment of persons with active TB
disease. In these circumstances, the risk for morbidity and mortality from TB disease is substantially greater
than with LTBI. Rifampin and PZA are essential components of recommended ATS/CDC/IDSA regimens
that render patients noninfectious rapidly and are effective in curing patients with drug-susceptible M.
tuberculosis strains within 6 months (5).
CDC continues to collect reports of severe liver injury leading to hospital admission or death in persons
receiving any treatment for LTBI. Health-care providers are encouraged to report such events to CDC's
Division of Tuberculosis Elimination, telephone 404-639-8442. Details of the RZ survey analysis and the
case series will be described in a separate publication.
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* The twice-weekly rifampin and pyrazinamide regimen for treatment of LTBI was specified to be completed within 2--3 months.
† Of the 11 deaths, eight were reported previously (1--3).
§ Representatives from state and local TB-control programs and health departments and hospitals, National TB Centers, ATS, the
National Coalition to Eliminate Tuberculosis, the National Tuberculosis Controllers Association, Infectious Diseases Society of
America, the American College of Chest Physicians, and CDC. CDC met separately with the Food and Drug Administration.
¶ In the interim revised recommendations, biochemical monitoring at 2, 4, and 6 weeks was recommended (2); however, because of
the occurrence of serious adverse events late in the course of RZ treatment, monitoring at 8 weeks has been added.
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